Rakovina Therapeutics Inc

Rakovina Therapeutics appointed Prof. Petra Hamerlik to the board of directors at the ordinary general meeting on 18 August 2026. Hamerlik holds the Chair of Translational Neuro-oncology at the University of Manchester and has been a member of Rakovina’s scientific advisory board since November 2023. She previously led CNS cancer biosciences at AstraZeneca and worked on brain-penetrant DNA repair inhibitors; her expertise is intended to strengthen research into AI-supported cancer therapies targeting the DNA damage response. » Plus sur de.investing.com

Rakovina Therapeutics sold 5,970,000 units at $0.10 each, raising $597,000 in the second and final tranche of a broker-free private placement. Across both tranches the company raised $1,991,000 gross; each unit consists of a common share and a half warrant, with a whole warrant exercisable within 24 months at $0.20. Insiders subscribed for a total of 2,120,000 units; the issued securities are subject to a hold period of four months and one day. The proceeds are intended primarily to advance the pipeline, notably kt-5000AI (ATR/mTOR program), kt-3000 LNP formulation, kt-2000AI and AI-driven lead-structure optimization using Variational AI; the closing is subject to final approval by the TSX Venture Exchange. » Plus sur de.investing.com